the Medicare sustainability question for high-cost chronic medications is real separate from the political framing - the population scale at which these medications would be used if fully covered through Medicare is large enough that the pricing structure that works for commercial insurance does not work at that volume without either dramatically lower per-unit cost or coverage limits. the negotiation mechanism is the lever that actually affects it, which is why the political fight around it matters practically